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Summary 
Cancer cells adapt metabolically to proliferate under nutrient limitation. Here we used 
combined transcriptional-metabolomic network analysis to identify metabolic 
pathways that support glucose-independent tumor cell proliferation. We found that 
glucose deprivation stimulated re-wiring of the tricarboxylic acid (TCA) cycle and 
early steps of gluconeogenesis to promote glucose-independent cell proliferation. 
Glucose limitation promoted the production of phosphoenolpyruvate (PEP) from 
glutamine via the activity of mitochondrial PEP-carboxykinase (PCK2). Under these 
conditions, glutamine-derived PEP was used to fuel biosynthetic pathways normally 
sustained by glucose, including serine and purine biosynthesis. PCK2 expression was 
required to maintain tumor cell proliferation under limiting glucose in vitro and tumor 
growth in vivo. Elevated PCK2 expression is observed in several human tumor types 
and enriched in tumor tissue from non-small-cell lung cancer (NSCLC) patients. Our 
results define a role for PCK2 in cancer cell metabolic reprogramming that promotes 
glucose-independent cell growth and metabolic stress resistance in human tumors. 
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Introduction 
One of the primary metabolic phenotypes observed in transformed cells is an increase 
in aerobic glycolysis (the “Warburg Effect”), which is marked by increased glucose 
uptake and lactate production. Glucose is used to generate ATP via glycolysis or 
mitochondrial oxidative phosphorylation (OXPHOS) (DeBerardinis et al., 2008a), 
while glycolytic intermediates also function as key substrates for macromolecular 
biosynthesis, supplying carbon for the synthesis of non-essential amino acids 
(NEAAs), intermediates of one-carbon metabolism, nucleotides, and lipids (Locasale, 
2013; Lunt and Vander Heiden, 2011). Another key nutrient for proliferating cancer 
cells is the NEAA glutamine. Proliferating cells maintain TCA cycle function using 
glutamine as an anapleurotic substrate to generate mitochondrial α-ketoglutarate (α-
KG) and subsequent biosynthetic intermediates (DeBerardinis et al., 2007). 
Glutamine enables the TCA cycle to function both as a carbon source for ATP 
production and a biosynthetic hub (Ahn and Metallo, 2015; Deberardinis et al., 
2008b). 
Much of our understanding of tumor cell metabolism is based on the 
metabolic programs engaged by cancer cells in vitro, where nutrient availability is in 
excess. However, glucose concentrations in tumors can be limiting - 3- to 10-fold 
lower than in non-transformed tissues (Birsoy et al., 2014; Hirayama et al., 2009) - 
due to a combination of reduced tumor vascularization and high rates of glucose 
consumption by cancer cells. Thus, tumor cells must enact strategies to grow and 
survive in metabolically unfavorable environments.  
Under limited glucose, cells capable of engaging OXPHOS have greater 
capacity to proliferate (Birsoy et al., 2014; Chen et al., 2015). Glutamine can partially 
compensate for glucose to maintain TCA cycle function under conditions of 
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metabolic stress. Acetyl-CoA can be generated from glutamine through reductive 
carboxylation of α-KG under conditions of hypoxia or reduced mitochondrial 
function (Metallo et al., 2012; Mullen et al., 2012; Wise et al., 2011). Similarly, TCA 
cycle function is maintained in glucose-deprived cells in part through the production 
of glutamine-derived pyruvate, which can be converted to acetyl-CoA and oxidized 
by mitochondria (Blagih et al., 2015; Le et al., 2012; Yang et al., 2014; Yang et al., 
2009). However, efficiency of OXPHOS and TCA cycle maintenance cannot fully 
account for cell proliferation under glucose limitation, as glycolytic intermediates are 
still required to generate biosynthetic precursors essential for cell division.  
 Here we have used metabolomic and transcriptional profiling to characterize 
pathways of glucose-independent tumor cell growth. Using this systems-level 
analysis, we have identified alterations in glutamine metabolism and the early steps of 
gluconeogenesis as key metabolic adaptations for tumor cells to proliferate under low 
glucose conditions. Here we describe a role for mitochondrial phosphoenolpyruvate 
(PEP) carboxykinase (PEPCK-M or PCK2) in mediating tumour cell adaptation to 
glucose limitation that facilitates tumor growth in vivo.  
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Results 
Network-based data integration reveals distinct metabolic nodes in tumor cells 
adapted to glucose-independent proliferation 
To gain insight into how cellular proliferation can be maintained under glucose-free 
conditions, we examined the growth of the NSCLC cell lines A549 and H1299, which 
are capable of proliferating in medium lacking glucose, but not glutamine (Figure 
1A). We performed a systems-level analysis of intracellular metabolites isolated from 
A549 cells cultured for 48 hours in the absence of glucose. The relative metabolite 
abundance in glucose-starved A549 cells is shown in Figure S1. Metabolite set 
enrichment analysis (MSEA) of these data revealed enrichment in metabolites 
involved in amino acid degradation (ammonia cycling, urea cycle), the TCA cycle, 
glutamate metabolism, and gluconeogenesis (Figure 1B). We next integrated RNA-
seq-based transcriptional profiling with our metabolic profiling data to construct a 
network-based analysis of possible metabolic fluxes (Jha et al., 2015). To trace all 
possible metabolic transformations of the labeled atoms, we constructed a metabolic 
network where individual nodes are individual carbon atoms connected by edges 
(connecting lines) corresponding to chemical reactions (totaling to about 30,000 
edges). From this we identified a sub-network based on connectivity and changes in 
metabolite abundance and metabolic enzyme gene expression under conditions of 
glucose deprivation (Figure 1C).  
From this network-based analysis we identified five major metabolic modules 
differentially regulated in A549 cells undergoing glucose-independent proliferation: 
glycolysis, the TCA cycle, glutamate/proline metabolism, inositol metabolism and 
serine metabolism (Figure 1C). Nodes for glycolysis and lactate production were, as 
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expected, significantly downregulated in A549 cells cultured under glucose-free 
conditions. Conversely, genes involved in inositol and proline metabolism were 
selectively upregulated under glucose withdrawal, while the intracellular 
concentration of several amino acids (serine, aspartate, asparagine, tryptophan and 
glycine) was also elevated. MSEA revealed enrichment in metabolites involved in 
glutamate metabolism and gluconeogenesis (Figure 1B). This is noteworthy because 
glutamine is a known gluconeogenic substrate (Stark and Kibbey, 2014). There is 
increased transamination of glutamate to α-KG (through ASNS and BCAT1), which 
is consistent with the increased glutamine dependence of A549 cells. The network 
also highlighted a significant upregulation in the conversion of oxaloacetate (OAA) to 
both aspartate (via GOT1) and PEP (via the gluconeogenic enzyme PCK2). Finally, 
increased levels of serine and glycine were coupled with transcriptional upregulation 
of PHGDH, an enzyme that directs glycolytic intermediates towards the serine 
biosynthesis pathway (Locasale, 2013). Taken together these data suggest an active 
role for glutamine as both a carbon and nitrogen source for amino acid metabolism, 
which may be achieved through the malate-aspartate shuttle and early steps of 
gluconeogenesis under low glucose conditions.  
  
Glutamine maintains TCA cycle metabolism and levels of the glycolytic 
intermediate PEP under glucose-free conditions 
Our transcriptional-metabolic network analysis indicated increased levels of 
glutamine metabolism in A549 cells proliferating in the absence of glucose. To 
characterize how glutamine is metabolized under glucose-free conditions, A549 cells 
were cultured in the presence of uniformly labeled 13C glutamine (U-[13C]-Q). 
Conventional metabolism of U-[13C]-glutamine in tumor cells is illustrated in Figure 
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2A. Similar 13C-labeling patterns were observed in glutamate and TCA cycle 
intermediates (α-KG, succinate, fumarate, and malate) under glucose-free and 
glucose-replete conditions (Figure 2B), indicating that glutamine continues to be used 
as an anaplerotic substrate for the TCA cycle when glucose is limiting. Levels of 13C-
glutamine-derived glutamate, succinate, and aspartate were increased under glucose 
withdrawal conditions, while the levels of many of the TCA cycle metabolites 
decreased under glucose withdrawal (Figure S2A), consistent with the network 
analysis in Figure 1C.  
Citrate production from glutamine was strikingly altered in A549 cells under 
glucose withdrawal. We observed a significant increase in the proportion of the citrate 
pool labeled from U-[13C]-glutamine, as shown by the large decrease in unlabeled 
citrate under glucose-free conditions (Figure 2C). The increased labeling of citrate 
from U-[13C]-glutamine was due to increases in both reductive carboxylation of α-KG 
(m+5 citrate) and the emergence of a fully labeled citrate molecule (m+6 citrate) 
(Figure 2C). Levels of m+6 citrate were negligible in A549 cells grown in the 
presence of glucose, but had not yet reached steady-state levels after 6 hours of 
labeling with U-[13C]-glutamine under glucose-free conditions (Figure 2D).  
Formation of m+6 citrate can occur if U-[13C]-glutamine is used to generate 
both OAA and acetyl-CoA, the latter requiring the formation of m+3 pyruvate from 
13C-glutamine (Figure S2B). It has been shown previously that the decarboxylation of 
glutamine-derived malate (m+4) can generate pyruvate m+3 through the activity of 
the malic enzyme (Guay et al., 2007; Yang et al., 2014). Alternatively, PEPCK can 
generate PEP (m+3) from OAA, followed by conversion of PEP to pyruvate by 
pyruvate kinase (PK). We found that while the overall abundance of pyruvate was 
lower in A549 cells growing in glucose-free conditions, the majority of pyruvate 
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(m+3) in these cells was derived from 13C-glutamine (Figure 2E). In addition, we 
observed a significant increase in U-[13C]-glutamine-derived PEP specifically in A549 
cells growing under glucose-free conditions (Figure 2F).  
Consistent with the network analysis (Figure 1C), lactate production was 
significantly downregulated in glucose-starved A549 cells (Figure S2C), and U-[13C]-
glutamine was not used for its synthesis. In contrast, glutamine was used in the 
synthesis of both pyruvate and PEP (Figure S2D). H1299 cells displayed similar 
increases in m+6 citrate, m+3 pyruvate, and m+3 PEP derived from 13C-glutamine 
specifically when growing under conditions of glucose withdrawal (Figure 2G). The 
presence of pyruvate m+3 and citrate m+6 suggests these cells are undergoing 
pyruvate cycling (Yang et al., 2014), using glutamine to maintain TCA function when 
glucose is unavailable. 
 
PCK2 is required for the production of glutamine-derived PEP 
Our RNA-seq results indicated that expression of the mitochondrial form of PEPCK  
(PCK2) was increased in A549 cells upon glucose withdrawal. However, no 
sequencing reads for PCK1, the cytosolic form of PEPCK, were detected (data not 
shown). Consistent with this, silencing PCK1 in A549 cells did not affect total 
PEPCK protein levels (Figure S3A). These data suggest that PCK2 is the sole PEPCK 
isoform expressed in A549 cells, in agreement with recent findings (Leithner et al., 
2014). 
 We next investigated the role of PCK2 in glutamine metabolism by silencing 
PCK2 expression in A549 and H1299 cells using RNA interference (Figure 3A) or 3-
mercaptopicolinic acid (MPA), a specific inhibitor of PEPCK activity (Urbina et al., 
1990). Conversion of U-[13C]-glutamine to PEP (Figure 3B) was stimulated by 
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glucose deprivation as before, but was markedly reduced in cells expressing PCK2 
shRNA or treated with MPA (Figure 3C). Glutamine flux into PEP was also ablated 
in glucose-starved A549 cells expressing PCK2 shRNA (Figure S3B). This effect 
appeared to be specific to the formation of PEP, as inhibiting PCK2 did not 
significantly affect TCA cycle anaplerosis from glutamine in A549 cells regardless of 
glucose availability (Figure S3C).  
To address whether PCK2 contributed to pyruvate cycling in A549 cells growing 
under glucose limitation (schematic in Figure 3B), we measured the formation of m+3 
pyruvate (Figure 3D) and m+6 citrate (Figure S3D) in cells expressing PCK2 shRNA. 
A549 cells expressing PCK2 shRNA displayed reduced labeling of pyruvate (m+3, 
Figure 3D) and citrate (m+6, Figure S3D) from U-[13C]-glutamine specifically under 
conditions of glucose withdrawal. Similarly, MPA treatment reduced the production 
of m+3 pyruvate from U-[13C]-glutamine in A549 cells growing in the absence of 
glucose (Figure 3D).  
 
Glutamine-derived PEP is used as a biosynthetic intermediate under low glucose 
conditions 
The reduced labeling of m+3 pyruvate and m+6 citrate upon PCK2 inhibition (Figure 
3D and S3D) was modest compared to the large reduction in m+3 PEP observed in 
NSCLC cells expressing PCK2 shRNA (Figure 3C), suggesting that glutamine-
derived PEP may be formed for a purpose other than pyruvate cycling. Our network 
analysis indicated a specific increase in the serine biosynthesis pathway in glucose-
deprived A549 cells (Figure 1C). Therefore, we assessed 13C enrichment in serine and 
glycine in A549 cells cultured with U-[13C]-glutamine under glucose-free conditions. 
13C-glutamine-derived carbon was detected in serine (Figure 4A and S4A) and glycine 
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(Figure 4B and S4A) from A549 cells undergoing glucose-independent proliferation. 
H1299 cells demonstrated a similar shift towards glutamine-dependent serine and 
glycine biosynthesis under glucose-free conditions, indicating that glutamine can 
substitute for glucose as a carbon source for serine biosynthesis (Figures 4C, 4D and 
S4B). The contribution of 13C-glutamine-derived carbon to the serine and glycine 
pools of glucose-starved A549 cells increased exponentially over time and did not 
reach steady-state labeling over the 6h labeling period (Figures 4A-B). Indeed, the 
contribution of 13C-glutamine-derived carbon to cellular serine and glycine pools 
reached 40% and 20%, respectively, when glucose-starved A549 cells were 
continuously labeled with 13C-glutamine for 48h (Figure S4C and D).    
 Next we addressed whether PCK2 could regulate the production of 13C-
glutamine-derived serine and glycine in tumor cells. Silencing PCK2 in A549 cells 
ablated the ability of glucose-starved cells to produce serine (Figure 4E) and glycine 
(Figure 4F) from U-[13C]-glutamine. 13C-glutamine flux into the serine biosynthesis 
pathway was completely ablated in glucose-starved cells expressing PCK2 shRNA 
(Figure S4E and F). Treatment of A549 cells with MPA also blocked glutamine-
dependent production of serine (Figure 4G).  
 We hypothesized that PEP generated from OAA is exported from the 
mitochondria (Passarella et al., 2003; Satrustegui et al., 2007), converted by enolase 
to 3-PG, and then directed into the serine biosynthesis pathway by the activity of 
PHGDH (Figure 4H). To test this, we measured 13C enrichment in serine (from U-
[13C]-glutamine tracer) in A549 cells with enolase or PHGDH expression silenced 
using siRNAs (Figure S4G). While levels of 13C-labeled serine from U-[13C]-
glutamine increased significantly upon glucose deprivation in control cells, cells 
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transfected with siRNAs targeting ENO1 or PHGDH displayed a marked reduction in 
glutamine-dependent serine biosynthesis (Figure S4H).  
Glucose-derived serine and glycine contribute to the synthesis of purine 
nucleotides required for cell proliferation (Lunt and Vander Heiden, 2011). Thus, we 
investigated whether glutamine could substitute for glucose in supplying carbon for 
purine biosynthesis by measuring 13C enrichment from U-[13C]-glutamine in the 
purine nucleotide ATP. We detected a significant increase in the abundance of 
glutamine-derived ATP in cells grown under glucose-free conditions, which was 
blocked in cells treated with MPA (Figure 4I). An increased proportion of ATP 
(~12%) was labeled from U-[13C]-glutamine, with the majority of the labeling at m+3 
(Figure 4J).  
 
PCK2 is required for glucose-independent cancer cell proliferation and tumor 
growth in vivo 
Silencing PCK2 by siRNA (Figure 5A) or shRNA (Figure S5B) blocked the ability of 
A549 and H1299 cells to proliferate in the absence of glucose. Consistent with the 
requirement of enolase and PHGDH to mediate glutamine-dependent serine 
biosynthesis (Figure S4H), knockdown of these enzymes also reduced the 
proliferation of A549 cells under glucose-free conditions (Figure 5B). Cell viability 
was unaffected by PCK2, ENO1 or PHGDH knockdown regardless of glucose 
availability (Figure S5C).  
 To assess the impact of PCK2 on tumor growth in vivo, A549 and H1299 cells 
expressing either control or PCK2-specific shRNAs (Figures S5D and F) were 
injected into the flanks of nude mice, and tumor growth assessed over 65 days 
(Figures 5C and E). The majority of tumors expressing control shRNAs grew steadily 
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over time; however, tumors expressing PCK2 shRNA failed to establish and grow 
substantially in vivo (Figures 5C and E). This was reflected in the reduced weight of 
PCK2 shRNA-expressing tumors at the end of the experiment (Figures 5D and F). 
PCK2 protein expression was readily detected in end-stage control tumors, while 
suppression of PCK2 protein levels was maintained in tumors derived from cells 
expressing PCK2 shRNA (Figures S5E and G).  
 
The hypoxia inducible factors HIF-1α  and EPAS1 regulate PCK2 expression 
under glucose limitation 
We next examined the mechanisms of PCK2 regulation by glucose availability. 
Expression of both PCK2 mRNA (Figure 6A) and protein (Figure 6B) was induced in 
NSCLC cells under conditions of glucose limitation. The activity of PCK2 is also 
dependent upon the production of mitochondrial GTP (mtGTP). mtGTP is generated 
by the SUCLG2 form of succinyl-CoA synthetase (SCS) in the TCA cycle (Stark et 
al., 2009). We found that the expression of the SUCLG2 transcript (Figure 6C) and its 
metabolite product succinate (Figure S2A) were both elevated in glucose-starved 
A549 cells. Notably, the expression of SUCLA2, the ATP-generating form of SCS, 
was not affected by glucose availability (Figure 6C). Consistent with the requirement 
of SUCLG2 expression for PCK2 activity, silencing of SUCLG2 (Figure S6A) led to 
a reduction in the glucose-independent proliferation of A549 cells (Figure 6D), 
similar to that observed when PCK2 is silenced (Figure 5A). Silencing SUCLA2 did 
not affect the glucose-independent proliferation of A549 cells (Figure 6D and S6A). 
The hypoxia-inducible transcription factors HIF-1α and EPAS1/HIF-2α can 
promote PCK2 expression in K-ras mutant tumor cells (Chun et al., 2010). To test the 
role of HIF-1α and EPAS1 in glucose-dependent control of PCK2 expression in our 
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system, these genes were silenced in A549 cells (Figure S6B). Glucose-dependent 
stimulation of PCK2 mRNA was not altered in A549 cells expressing HIF-1α siRNA, 
and only partially reduced upon EPAS1 knockdown (Figure S6C). However, 
silencing both HIF-1α and EPAS1 led to a ~25% reduction in PCK2 mRNA 
expression. Similarly, silencing both HIF-1α and EPAS1 prevented the full induction 
of PCK2 protein by glucose withdrawal (Figure 6E).  
Finally, we assessed the impact of HIF expression during glucose-independent 
proliferation. Knockdown of HIF-1α or EPAS1 alone had minimal effects on cell 
proliferation, while silencing both impaired the ability of A549 cells to proliferate 
under glucose-free conditions (Figure 6F).  
  
PCK2 expression is deregulated in human cancer 
We next investigated PCK2 expression in human tumors through analysis of TCGA 
expression datasets for a variety of tumor types. PCK2 mRNA expression was 
increased in a variety of tumor types (Figure 7A). The highest PCK2 expression was 
found in thyroid, bladder, breast, kidney and NSCLC cancer tissue (Figure 7A). We 
next asked if elevated PCK2 expression was observed in subsets of tumors within 
different tumor types. We considered the relative fraction of tumors with a z-score for 
PCK2 >2 (illustrated by outlier dots on boxplots in Figure 7A, and summarized in the 
bottom panel). PCK2 was overexpressed in 8.8% of lung squamous cell carcinoma 
(one of the major subtypes of NSCLC) samples from the TCGA datasets analyzed, 
which was the largest fraction among all tumor types examined. 
 We also assessed PCK2 protein levels in tumor samples isolated from human 
NSCLC patients. Examples of PCK2 protein expression in normal and tumor tissue 
from the lungs of 7 NSCLC patients are shown in Figure 7B, while Figure S7 presents 
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PCK2 protein levels in normal and tumor tissue from each of the 29 patients analyzed. 
Quantification of PCK2 protein expression in these primary human lung cancer 
samples revealed a significant increase in PCK2 protein levels in 15/29 (52%) of lung 
tumors (at p<0.05; Kruskal-Wallis test) when compared to patient-matched normal 
tissue (Figure 7C), compared to a decrease in PCK2 expression in only 10% of tumors 
(3/29, p<0.05). Together these data indicate that PCK2 expression is enriched in a 
number of tumor types, including NSCLC. 
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Discussion 
Glucose is an important carbon source for proliferating cells, and is used to generate 
both ATP and precursors for macromolecular synthesis (Lunt and Vander Heiden, 
2011). However, reduced glucose availability combined with the high demand for 
nutrients by cancer cells can lead to metabolic stress in tumors (Cantor and Sabatini, 
2012; Jones and Thompson, 2009). Mounting evidence indicates that cancer cells and 
some non-malignant cells can engage glucose-independent metabolism to maintain 
cell proliferation and viability when glucose is limiting (Birsoy et al., 2014; Blagih et 
al., 2015; Glick et al., 2014; Le et al., 2012; Pasto et al., 2014). Tumor cells capable 
of using alternate substrates for biosynthetic and bioenergetic needs would gain a 
survival and proliferative advantage in microenvironments with limited resources. 
Using systems-level analysis combining both transcriptional and metabolic profiling 
data, we have identified the gluconeogenic enzyme PCK2 as a key regulator of tumor 
cell metabolic flexibility. We demonstrate here that PCK2 mediates a metabolic shunt 
in response to glucose deprivation, which supplies carbon from glutamine, rather than 
glucose, to generate glycolytic pathway intermediates required for biosynthesis and 
cell proliferation. Our data implicate PCK2-dependent metabolic reprogramming as a 
mechanism for glucose-independent tumor cell growth.  
TCA cycle metabolism and OXPHOS are essential for maintaining energetic 
homeostasis in glucose-starved cells. This is achieved in part by glutamine-dependent 
pyruvate cycling through malic enzyme activity (Guay et al., 2007). Our data indicate 
that pyruvate cycling can also be mediated by PCK2 in glucose-starved tumor cells 
similar to that observed in pancreatic β-cells (Stark et al., 2009). However, silencing 
PCK2 in glucose-starved A549 cells only modestly affected pyruvate cycling, 
suggesting alternate fates for PEP in tumor cells. We found that PCK2-dependent 
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production of PEP could also provide tumor cells growing in a low glucose 
environment with a supply of glycolytic intermediates needed to maintain cell 
proliferation.  
Serine biosynthesis is a key metabolic pathway for cell proliferation, 
contributing carbon to many anabolic processes such as protein, glutathione, 
nucleotide, and phospholipid biosynthesis (Locasale, 2013; Vander Heiden et al., 
2011). Under standard growth conditions, either exogenous serine or serine generated 
de novo from the glycolytic intermediate 3-phosphoglycerate (3-PG) can be used for 
anabolic growth (Chaneton et al., 2012; Labuschagne et al., 2014; Locasale et al., 
2011). Here, we demonstrate that glutamine can substitute for glucose in serine and 
glycine biosynthesis in tumor cells with elevated PCK2 expression. Interestingly, 
despite the availability of exogenous serine and glycine, PHGDH was still required 
for tumor cell proliferation under low glucose conditions, suggesting that flux through 
this pathway contributes to cell growth even when the end products of the pathway 
are plentiful. PHGDH amplification is observed in some cancers (Locasale et al., 
2011; Possemato et al., 2011), which may provide metabolic flexibility to tumors by 
fueling serine biosynthesis from multiple carbon sources. 
Our results also indicate that glutamine can be used as a carbon source for 
nucleotide biosynthesis under conditions of glucose deprivation. Two carbons in 
purine nucleotides are derived from glycine and two one-carbon units are provided by 
N-10-formyl-tetrahydrofolate, which acquires most of their carbon units from serine 
(Lunt and Vander Heiden, 2011). Thus, de novo serine biosynthesis could account for 
the 13C-glutamine labeling patterns we observed in ATP. Another possibility is that 
13C-glutamine-derived glyceraldehyde 3-phosphate enters the non-oxidative arm of 
the pentose phosphate pathway to generate 5-phosphoribosyl-α-pyrophosphate 
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(PRPP) for nucleotide biosynthesis. It is unclear whether glutamine is sufficient to 
supply the glycolytic intermediates to generate nucleotide sugars, or whether these are 
sourced from other nutrients in glucose starved cells.  
Increased glutamine/glutamate metabolism forms only one node of the 
metabolic adaptation network mediated by PCK2, suggesting that other substrates 
may feed into the network to help supply biosynthetic intermediates. Recent work 
suggests that PCK2 can mediate the conversion of lactate to PEP in lung cancer cells 
(Leithner et al., 2014), although this would require a supply of lactate from the tumor 
microenvironment as very little lactate is found in tumor cells experiencing glucose 
deprivation. Other anapleurotic substrates capable of generating OAA could function 
as substrates for PCK2-dependent PEP production under low glucose conditions, such 
as branched chain amino acids (BCAAs), which can enter the TCA cycle through 
metabolism of propionyl-CoA (Stark and Kibbey, 2014). Fructose-1,6-
bisphosphatase, another enzyme involved in gluconeogenesis, can promote the 
viability of metastatic breast cancer cells by increasing glutamine and BCAA 
metabolism (Chen et al., 2015). Indeed, branched-chain amino acid transaminase 1 
(BCAT1) is significantly upregulated in our metabolic network, as are the levels of 
several BCAAs (leucine, valine and isoleucine). β-oxidation of lipids may provide 
another carbon source for biosynthetic growth under glucose limitation (Vacanti et al., 
2014).  
PCK2 appears to be a glucose-regulated gene, as both mRNA and protein 
levels are significantly induced upon glucose withdrawal in tumor cells. PCK2 
activity also depends on mitochondrial GTP (mtGTP), which is generated by the 
SUCLG2 form of succinyl-CoA synthetase (SCS) in the mitochondrial matrix (Stark 
et al., 2009). Expression of both SUCLG2 and PCK2 mRNA are stimulated by 
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glucose withdrawal, suggesting a coordinated effort to enhance PCK2 activity under 
low glucose conditions. Our data indicate that HIF-1α and EPAS1/HIF-2α act 
synergistically to induce PCK2 expression and facilitate proliferation under glucose-
free conditions. While HIF-1α has been implicated in gluconeogenesis and regulation 
of PCK1 expression in the liver (Choi et al., 2005; Tajima et al., 2009), PCK1 was not 
abundantly expressed in NSCLC cells, nor was HIF-1α alone required for PCK2 
expression, suggesting a more prominent role for EPAS1/HIF-2α in glucose-
dependent control of PCK2. Thus, while HIFs play prominent roles in metabolic 
regulation during hypoxia (Mucaj et al., 2012), HIF-dependent re-wiring of the TCA 
cycle through PCK2 helps provide tumor cells with additional metabolic flexibility 
for glucose-independent cell growth.  
To date, there has been little focus on PEPCK in the context of cancer. Here 
we have presented evidence for PCK2-mediated metabolic adaptation in tumor cells 
and elevated PCK2 expression in human tumor subsets including NSCLC. We 
hypothesize that PCK2 could provide a selective growth advantage to tumor cells 
growing in nutrient-poor environments, enabling them to use PEP, supplied by 
glutamine or other anapleurotic substrates, to support TCA cycle metabolism and 
glycolytic intermediates for biosynthesis. In this light, targeting PCK2-mediated 
metabolic adaptation may be an effective strategy for certain cancer subtypes, 
particularly NSCLC. 
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Experimental Procedures 
Cell culture 
A549 and H1299 cell lines were obtained from ATCC (Manassas, VA, USA). Cells 
were cultured in ‘growth medium’ (DMEM (A549 cells) or RPMI (H1299 cells)) 
supplemented with 10% fetal bovine serum (FBS), penicillin, streptomycin, 
glutamine, and non-essential amino acids (for H1299 cells). For glucose limitation 
experiments, cells were cultured in glucose- and glutamine-free DMEM 
supplemented with 10% dialysed FBS (Wisent, Saint-John-Baptiste, QC, Canada) and 
glutamine (2 mM) and glucose (25 mM) added as required. PCK2 knockdown was 
achieved using lentiviral shRNA vectors from the TRC shRNA collection (ID 
numbers listed in Supplementary Information). Lentiviral supernatants were generated 
as described (Huang et al., 2012). Transient knockdown of PCK2, ENO1, PHGDH, 
HIF1A, EPAS1, SUCLG2 and SUCLA2 was achieved using the SMARTpool ON-
TARGETplus siRNA reagent (composed of 4 individual siRNAs for each target) from 
GE Dharmacon (Layette, CO, USA). The PEPCK inhibitor 3-mercaptopicolinic acid 
(MPA) was obtained from Santa Cruz Biotechnology (Dallas, TX, USA).  
 
Cell proliferation and viability assays 
Cells were seeded in 384 well plates (500 cells/well) in growth medium as previously 
described (Vincent et al., 2015). After 24h, growth medium was replaced with fresh 
medium containing 25 or 0 mM glucose. Cells were fixed with 4% formaldehyde, 
stained with Hoechst DNA stain, and cell number determined by nuclei counting. 
Images were taken using an Operetta High Content Imaging System and analyzed 
using Harmony High Content Imaging and Analysis Software (Perkin Elmer, 
Waltham, MA, USA). Cell viability was determined by viability dye exclusion by 
! 21!
flow cytometry using propidium iodide (PI). Cells were analyzed using a Gallios flow 
cytometer (Beckman Coulter, Fullerton, CA) and data analyzed using FlowJo 
software (TreeStar). 
 
Metabolite Profiling by GC- and LC-MS 
Cellular metabolites were extracted and analyzed either by GC-MS or LC-MS using 
previously described protocols (Dupuy et al., 2013; Faubert et al., 2014; McGuirk et 
al., 2013). For GC-MS, metabolite extracts were derivatized using N-(tert-
butyldimethylsilyl)-N-methyltrifluoroacetamide (MTBSTFA) as previously described 
(Faubert et al., 2013). D-myristic acid (750 ng/sample) was added as an internal 
standard to metabolite extracts, and metabolite abundance was expressed relative to 
the internal standard and normalized to cell number. Liquid chromatography was 
performed using a 1290 Infinity ultra-performance LC system (Agilent Technologies, 
Santa Clara, CA, USA) equipped with a Scherzo 3 μm, 3.0×150mm SM-C18 column 
(Imtakt Corp, Japan). LC-MS analysis was performed on an Agilent 6540 UHD 
Accurate-Mass Q-TOF mass spectrometer (Agilent Technologies, Santa Clara, CA, 
USA). For SITA experiments, cells were cultured with U-[13C]-glutamine (Cambridge 
Isotopes) for the times indicated. Mass isotopomer distribution was determined using 
a custom algorithm developed at McGill University (McGuirk et al., 2013). 
 
RNA-Seq analysis and Network-based Data Integration 
For RNA-seq experiments, A549 cells were cultured in the presence or absence of 
glucose (25 mM) for 48 hours prior to RNA extraction. cDNA synthesis and library 
construction was conducted as previously described (Jha et al., 2015). Libraries were 
sequenced using a HiSeq 2500 (Illumina) using 50bpX25bp pair-end sequencing.  
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To construct the integrated metabolic network illustrated in Figure 1, A549 
cells were cultured in medium containing 25 or 0 mM glucose for 48 hours prior to 
either RNA or metabolite extraction and analysis. Integration of metabolite and RNA 
expression datasets was conducted as previously described (Jha et al., 2015). 
Additional details are provided in Supplementary Information. 
 
Immunoblotting and Quantitative Real-Time PCR 
Lysates of NSCLC cell lines or tissue were subjected to SDS-PAGE and western 
blotting as previously described (Vincent et al., 2011). Primary antibodies to PCK2 
and actin, as well as HRP-conjugated anti-rabbit and anti-mouse secondary antibodies 
were obtained from Cell Signaling Technology (Danvers, MA, USA). All human 
NSCLC tissue lysate immunoblots were incubated with fluorescently labeled anti-
rabbit or anti-mouse secondary antibodies and analyzed and quantified using an 
Odyssey® Sa Infrared Imaging System (Licor, Lincoln, NE, USA). Quantitative PCR 
was performed as previously described (Faubert et al., 2013). Primer sequences have 
previously been described (Faubert et al., 2013) or are listed in Table S1.  
 
Tumor xenograft assays 
A549 and H1299 cells expressing either control or shRNA targeting PCK2 were 
counted (2 million cells/injection) and resuspended in 50% matrigel/50% PBS 
(200μl/injection) and injected subcutaneously into the flanks of nude mice (Charles 
River, Seattle, WA, USA). Tumor length (l) and width (w) was measured every 3-4 
days with calipers and the tumor volume (V) was calculated (V=1/2(lxw2)). After 65 
days the mice were sacrificed and the tumors were dissected out and weighed.  
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TCGA data analysis 
TCGA data for 35 tumor studies that contained mRNA expression data was accessed 
using the R-interface cgdsr to cBio Cancer Genomics Portal (Cerami et al., 2012; Gao 
et al., 2013). For each dataset, PCK2 expression relative to ACTB was determined for 
each patient sample. Nine studies with different tissues from the whole spectrum of 
relative PCK2 expression were analyzed. 
 
NSCLC patients and tissue samples 
Collection of samples, details of the cohort and sample extraction have been 
previously described (Vincent et al., 2014; Vincent et al., 2011). Briefly, three distinct 
samples of lung tumour tissue and adjacent normal lung from the resection margin 
were taken, flash frozen in liquid nitrogen, and stored at −80°C until further analysis. 
Only those NSCLC tumour samples comprising at least 90% tumour tissue were 
analyzed. Tissues were homogenized in 1% NP40 lysis buffer using a Polytron 
homogenizer to generate tissue lysates for SDS-PAGE analysis.  
 
Statistical Analysis 
Statistics were determined using paired Student’s t-test using Prism software 
(GraphPad, San Diego, CA, USA) unless otherwise stated. Data are calculated as the 
mean ± SEM for biological triplicates unless otherwise stated. Statistical significance 
is represented in figures by: *, p<0.05; **, p<0.01; ***, p<0.001; ****, p<0.0001. 
  
! 24!
Acknowledgements 
We acknowledge M Hetzel, J Pawade, M Sohail and L Phillips for the collection of 
NSCLC tissue. W Reintsch gave technical assistance and S Huang provided access to 
the shRNAs. The work was supported by grants from the McGill Integrated Cancer 
Research Training Program (to EEV, PPC and BRF), the Government of Russian 
Federation (to AS, 074-U01), Fonds de recherche Santé Québec (TG), Wellcome 
Trust Seeding Drug Discovery Award (to JMT) and CIHR (MOP-93799), Terry Fox 
Foundation, and Cancer Research Society (to RGJ). 
 
  
! 25!
Accession Numbers 
Raw and processed sequencing data are deposited at Pubmed GEO under GSE66556. 
  
! 26!
References 
Ahn, C.S., and Metallo, C.M. (2015). Mitochondria as biosynthetic factories for 
cancer proliferation. Cancer & metabolism 3, 1. 
Birsoy, K., Possemato, R., Lorbeer, F.K., Bayraktar, E.C., Thiru, P., Yucel, B., Wang, 
T., Chen, W.W., Clish, C.B., and Sabatini, D.M. (2014). Metabolic determinants of 
cancer cell sensitivity to glucose limitation and biguanides. Nature 508, 108-112. 
Blagih, J., Coulombe, F., Vincent, E.E., Dupuy, F., Galicia-Vazquez, G., Yurchenko, 
E., Raissi, T.C., van der Windt, G.J., Viollet, B., Pearce, E.L., et al. (2015). The 
Energy Sensor AMPK Regulates T Cell Metabolic Adaptation and Effector 
Responses In Vivo. Immunity 42, 41-54. 
Cantor, J.R., and Sabatini, D.M. (2012). Cancer cell metabolism: one hallmark, many 
faces. Cancer discovery 2, 881-898. 
Cerami, E., Gao, J., Dogrusoz, U., Gross, B.E., Sumer, S.O., Aksoy, B.A., Jacobsen, 
A., Byrne, C.J., Heuer, M.L., Larsson, E., et al. (2012). The cBio cancer genomics 
portal: an open platform for exploring multidimensional cancer genomics data. 
Cancer discovery 2, 401-404. 
Chaneton, B., Hillmann, P., Zheng, L., Martin, A.C., Maddocks, O.D., 
Chokkathukalam, A., Coyle, J.E., Jankevics, A., Holding, F.P., Vousden, K.H., et al. 
(2012). Serine is a natural ligand and allosteric activator of pyruvate kinase M2. 
Nature 491, 458-462. 
Chen, J., Lee, H.J., Wu, X., Huo, L., Kim, S.J., Xu, L., Wang, Y., He, J., Bollu, L.R., 
Gao, G., et al. (2015). Gain of glucose-independent growth upon metastasis of breast 
cancer cells to the brain. Cancer Res 75, 554-565. 
! 27!
Choi, J.H., Park, M.J., Kim, K.W., Choi, Y.H., Park, S.H., An, W.G., Yang, U.S., and 
Cheong, J. (2005). Molecular mechanism of hypoxia-mediated hepatic 
gluconeogenesis by transcriptional regulation. FEBS Lett 579, 2795-2801. 
Chun, S.Y., Johnson, C., Washburn, J.G., Cruz-Correa, M.R., Dang, D.T., and Dang, 
L.H. (2010). Oncogenic KRAS modulates mitochondrial metabolism in human colon 
cancer cells by inducing HIF-1alpha and HIF-2alpha target genes. Molecular cancer 
9, 293. 
DeBerardinis, R.J., Lum, J.J., Hatzivassiliou, G., and Thompson, C.B. (2008a). The 
biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell 
Metab 7, 11-20. 
DeBerardinis, R.J., Mancuso, A., Daikhin, E., Nissim, I., Yudkoff, M., Wehrli, S., and 
Thompson, C.B. (2007). Beyond aerobic glycolysis: transformed cells can engage in 
glutamine metabolism that exceeds the requirement for protein and nucleotide 
synthesis. Proc Natl Acad Sci U S A 104, 19345-19350. 
Deberardinis, R.J., Sayed, N., Ditsworth, D., and Thompson, C.B. (2008b). Brick by 
brick: metabolism and tumor cell growth. Curr Opin Genet Dev 18, 54-61. 
Dupuy, F., Griss, T., Blagih, J., Bridon, G., Avizonis, D., Ling, C., Dong, Z., Siwak, 
D.R., Annis, M.G., Mills, G.B., et al. (2013). LKB1 is a central regulator of tumor 
initiation and pro-growth metabolism in ErbB2-mediated breast cancer. Cancer & 
metabolism 1, 18. 
Faubert, B., Boily, G., Izreig, S., Griss, T., Samborska, B., Dong, Z., Dupuy, F., 
Chambers, C., Fuerth, B.J., Viollet, B., et al. (2013). AMPK Is a Negative Regulator 
! 28!
of the Warburg Effect and Suppresses Tumor Growth In Vivo. Cell Metab 17, 113-
124. 
Faubert, B., Vincent, E.E., Griss, T., Samborska, B., Izreig, S., Svensson, R.U., 
Mamer, O.A., Avizonis, D., Shackelford, D.B., Shaw, R.J., et al. (2014). Loss of the 
tumor suppressor LKB1 promotes metabolic reprogramming of cancer cells via HIF-
1alpha. Proc Natl Acad Sci U S A 111, 2554-2559. 
Gao, J., Aksoy, B.A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S.O., Sun, Y., 
Jacobsen, A., Sinha, R., Larsson, E., et al. (2013). Integrative analysis of complex 
cancer genomics and clinical profiles using the cBioPortal. Sci Signal 6, pl1. 
Glick, G.D., Rossignol, R., Lyssiotis, C.A., Wahl, D., Lesch, C., Sanchez, B., Liu, X., 
Hao, L.Y., Taylor, C., Hurd, A., et al. (2014). Anaplerotic metabolism of alloreactive 
T cells provides a metabolic approach to treat graft-versus-host disease. J Pharmacol 
Exp Ther 351, 298-307. 
Guay, C., Madiraju, S.R., Aumais, A., Joly, E., and Prentki, M. (2007). A role for 
ATP-citrate lyase, malic enzyme, and pyruvate/citrate cycling in glucose-induced 
insulin secretion. J Biol Chem 282, 35657-35665. 
Hirayama, A., Kami, K., Sugimoto, M., Sugawara, M., Toki, N., Onozuka, H., 
Kinoshita, T., Saito, N., Ochiai, A., Tomita, M., et al. (2009). Quantitative 
metabolome profiling of colon and stomach cancer microenvironment by capillary 
electrophoresis time-of-flight mass spectrometry. Cancer Res 69, 4918-4925. 
Huang, S., Holzel, M., Knijnenburg, T., Schlicker, A., Roepman, P., McDermott, U., 
Garnett, M., Grernrum, W., Sun, C., Prahallad, A., et al. (2012). MED12 controls the 
! 29!
response to multiple cancer drugs through regulation of TGF-beta receptor signaling. 
Cell 151, 937-950. 
Jha, A.K., Huang, S.C.-C., Sergushichev, A., Lampropoulou, V., Ivanova, Y., 
Loginicheva, E., Chmielewski, K., Stewart, K.M., Ashall, J., Everts, B., et al. (2015). 
Network integration of parallel metabolomic-transcriptional data reveals novel 
metabolic modules regulating divergent macrophage polarization. Immunity 42, 419-
430. 
Jones, R.G., and Thompson, C.B. (2009). Tumor suppressors and cell metabolism: a 
recipe for cancer growth. Genes Dev 23, 537-548. 
Labuschagne, C.F., van den Broek, N.J., Mackay, G.M., Vousden, K.H., and 
Maddocks, O.D. (2014). Serine, but not glycine, supports one-carbon metabolism and 
proliferation of cancer cells. Cell reports 7, 1248-1258. 
Le, A., Lane, A.N., Hamaker, M., Bose, S., Gouw, A., Barbi, J., Tsukamoto, T., 
Rojas, C.J., Slusher, B.S., Zhang, H., et al. (2012). Glucose-independent glutamine 
metabolism via TCA cycling for proliferation and survival in B cells. Cell Metab 15, 
110-121. 
Leithner, K., Hrzenjak, A., Trotzmuller, M., Moustafa, T., Kofeler, H.C., 
Wohlkoenig, C., Stacher, E., Lindenmann, J., Harris, A.L., Olschewski, A., et al. 
(2014). PCK2 activation mediates an adaptive response to glucose depletion in lung 
cancer. Oncogene. 
Locasale, J.W. (2013). Serine, glycine and one-carbon units: cancer metabolism in 
full circle. Nat Rev Cancer 13, 572-583. 
! 30!
Locasale, J.W., Grassian, A.R., Melman, T., Lyssiotis, C.A., Mattaini, K.R., Bass, 
A.J., Heffron, G., Metallo, C.M., Muranen, T., Sharfi, H., et al. (2011). 
Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to 
oncogenesis. Nature genetics 43, 869-874. 
Lunt, S.Y., and Vander Heiden, M.G. (2011). Aerobic glycolysis: meeting the 
metabolic requirements of cell proliferation. Annual review of cell and developmental 
biology 27, 441-464. 
McGuirk, S., Gravel, S.P., Deblois, G., Papadopoli, D.J., Faubert, B., Wegner, A., 
Hiller, K., Avizonis, D., Akavia, U.D., Jones, R.G., et al. (2013). PGC-1alpha 
supports glutamine metabolism in breast cancer. Cancer & metabolism 1, 22. 
Metallo, C.M., Gameiro, P.A., Bell, E.L., Mattaini, K.R., Yang, J., Hiller, K., Jewell, 
C.M., Johnson, Z.R., Irvine, D.J., Guarente, L., et al. (2012). Reductive glutamine 
metabolism by IDH1 mediates lipogenesis under hypoxia. Nature 481, 380-384. 
Mucaj, V., Shay, J.E., and Simon, M.C. (2012). Effects of hypoxia and HIFs on 
cancer metabolism. International journal of hematology 95, 464-470. 
Mullen, A.R., Wheaton, W.W., Jin, E.S., Chen, P.H., Sullivan, L.B., Cheng, T., Yang, 
Y., Linehan, W.M., Chandel, N.S., and DeBerardinis, R.J. (2012). Reductive 
carboxylation supports growth in tumour cells with defective mitochondria. Nature 
481, 385-388. 
Passarella, S., Atlante, A., Valenti, D., and de Bari, L. (2003). The role of 
mitochondrial transport in energy metabolism. Mitochondrion 2, 319-343. 
! 31!
Pasto, A., Bellio, C., Pilotto, G., Ciminale, V., Silic-Benussi, M., Guzzo, G., Rasola, 
A., Frasson, C., Nardo, G., Zulato, E., et al. (2014). Cancer stem cells from epithelial 
ovarian cancer patients privilege oxidative phosphorylation, and resist glucose 
deprivation. Oncotarget 5, 4305-4319. 
Possemato, R., Marks, K.M., Shaul, Y.D., Pacold, M.E., Kim, D., Birsoy, K., 
Sethumadhavan, S., Woo, H.K., Jang, H.G., Jha, A.K., et al. (2011). Functional 
genomics reveal that the serine synthesis pathway is essential in breast cancer. Nature 
476, 346-350. 
Satrustegui, J., Pardo, B., and Del Arco, A. (2007). Mitochondrial transporters as 
novel targets for intracellular calcium signaling. Physiological reviews 87, 29-67. 
Stark, R., and Kibbey, R.G. (2014). The mitochondrial isoform of 
phosphoenolpyruvate carboxykinase (PEPCK-M) and glucose homeostasis: has it 
been overlooked? Biochim Biophys Acta 1840, 1313-1330. 
Stark, R., Pasquel, F., Turcu, A., Pongratz, R.L., Roden, M., Cline, G.W., Shulman, 
G.I., and Kibbey, R.G. (2009). Phosphoenolpyruvate cycling via mitochondrial 
phosphoenolpyruvate carboxykinase links anaplerosis and mitochondrial GTP with 
insulin secretion. J Biol Chem 284, 26578-26590. 
Tajima, T., Goda, N., Fujiki, N., Hishiki, T., Nishiyama, Y., Senoo-Matsuda, N., 
Shimazu, M., Soga, T., Yoshimura, Y., Johnson, R.S., et al. (2009). HIF-1alpha is 
necessary to support gluconeogenesis during liver regeneration. Biochem Biophys 
Res Commun 387, 789-794. 
Urbina, J.A., Osorno, C.E., and Rojas, A. (1990). Inhibition of phosphoenolpyruvate 
carboxykinase from Trypanosoma (Schizotrypanum) cruzi epimastigotes by 3-
! 32!
mercaptopicolinic acid: in vitro and in vivo studies. Archives of biochemistry and 
biophysics 282, 91-99. 
Vacanti, N.M., Divakaruni, A.S., Green, C.R., Parker, S.J., Henry, R.R., Ciaraldi, 
T.P., Murphy, A.N., and Metallo, C.M. (2014). Regulation of substrate utilization by 
the mitochondrial pyruvate carrier. Mol Cell 56, 425-435. 
Vander Heiden, M.G., Lunt, S.Y., Dayton, T.L., Fiske, B.P., Israelsen, W.J., Mattaini, 
K.R., Vokes, N.I., Stephanopoulos, G., Cantley, L.C., Metallo, C.M., et al. (2011). 
Metabolic pathway alterations that support cell proliferation. Cold Spring Harb Symp 
Quant Biol 76, 325-334. 
Vincent, E.E., Coelho, P.P., Blagih, J., Griss, T., Viollet, B., and Jones, R.G. (2015). 
Differential effects of AMPK agonists on cell growth and metabolism. Oncogene. 34, 
3627-39. 
Vincent, E.E., Elder, D.J., O'Flaherty, L., Pardo, O.E., Dzien, P., Phillips, L., Morgan, 
C., Pawade, J., May, M.T., Sohail, M., et al. (2014). Glycogen synthase kinase 3 
protein kinase activity is frequently elevated in human non-small cell lung carcinoma 
and supports tumour cell proliferation. PLoS One 9, e114725. 
Vincent, E.E., Elder, D.J., Phillips, L., Heesom, K.J., Pawade, J., Luckett, M., Sohail, 
M., May, M.T., Hetzel, M.R., and Tavare, J.M. (2011). Overexpression of the 
TXNDC5 protein in non-small cell lung carcinoma. Anticancer Res 31, 1577-1582. 
Wise, D.R., Ward, P.S., Shay, J.E., Cross, J.R., Gruber, J.J., Sachdeva, U.M., Platt, 
J.M., DeMatteo, R.G., Simon, M.C., and Thompson, C.B. (2011). Hypoxia promotes 
isocitrate dehydrogenase-dependent carboxylation of alpha-ketoglutarate to citrate to 
support cell growth and viability. Proc Natl Acad Sci U S A 108, 19611-19616. 
! 33!
Yang, C., Ko, B., Hensley, C.T., Jiang, L., Wasti, A.T., Kim, J., Sudderth, J., 
Calvaruso, M.A., Lumata, L., Mitsche, M., et al. (2014). Glutamine oxidation 
maintains the TCA cycle and cell survival during impaired mitochondrial pyruvate 
transport. Mol Cell 56, 414-424. 
Yang, C., Sudderth, J., Dang, T., Bachoo, R.G., McDonald, J.G., and DeBerardinis, 
R.J. (2009). Glioblastoma cells require glutamate dehydrogenase to survive 
impairments of glucose metabolism or Akt signaling. Cancer Res 69, 7986-7993. 
 
  
! 34!
Figure Legends 
Figure 1. Network-based data integration reveals distinct metabolic nodes in 
tumor cells adapted to glucose-independent proliferation. 
 (A) Proliferation of A549 and H1299 cells over 96h in either nutrient replete medium 
(+Glc, +Q), medium without glucose (-Glc, +Q) or medium without glutamine (+Glc, 
-Q). Data are represented as mean +/- SEM for biological replicates (n=5). 
 (B) Metabolite set enrichment analysis for differentially regulated metabolic 
pathways induced upon glucose deprivation. A549 cells were cultured in the presence 
(Glc+) or absence (Glc-) of glucose for 48h before metabolite abundances were 
determined by GC and LC-MS (full metabolite profile in Figure S1).  
(C) Integrated metabolic network analysis for A549 cells cultured in the presence 
(Glc+) or absence (Glc-) of glucose for 48h. The direction and magnitude of the fold-
change in enzyme expression or metabolite abundance between conditions is 
indicated on a red (enriched in Glc-) to green (enriched in Glc+) color scale. Enzymes 
are represented by edges (connecting lines between metabolites) with the color of the 
edge indicating fold-change and the thickness reflecting the significance of 
differential expression. Round nodes represent metabolites, with the differential 
abundance of each metabolite indicated by the size of the node. Major features of 
glucose deprivation identified by the network analysis are highlighted by bold titles 
and background shading.  
 
Figure 2. Glucose withdrawal redirects glutamine metabolism to maintain the 
TCA cycle and for the production of PEP. 
(A) Model of glutamine dependent anapleurosis in the TCA cycle. U-[13C]-Q fuels 
TCA cycle anaplerosis through α-KG to OAA via succinate, fumarate and malate. 
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Oxidative metabolism of glutamine yields citrate m+4, while reductive carboxylation 
of glutamine results in citrate m+5. Abbreviations: Glc, glucose; Gln, glutamine; Ac-
CoA, acety-CoA; α-KG, α-ketoglutarate; OAA, oxaloacetate. 
(B) Proportion of glutamate and α-KG containing five 13C carbons (m+5) and the 
proportion of succinate, fumarate, malate and aspartate containing four 13C carbons 
(m+4) in A549 cells cultured for 12h in the presence (+) or absence (-) of unlabeled 
glucose (Glc). Cells were cultured with U-[13C]-Q for the last 6h. 
(C) Mass isotopologues of the citrate pool in A549 cells, cultured as in (B). 
(D) Contribution of the mass isotopologues of citrate (m+4, m+5 and m+6) to the 
total citrate pool in A549 cells. Cells were pre-incubated in the presence or absence of 
glucose for 6h before incubation with U-[13C]-Q (time 0).  Cells extracts were 
harvested at the time points shown.  
(E-F) Glutamine contribution to pyruvate and PEP in glucose starved A549 cells. (E) 
Top: Relative abundance and contribution of U-[13C]-Q to pyruvate in A549 cells 
cultured as in (B). Bottom: Proportion of the pyruvate pool labeled by U-[13C]-Q over 
time in A549 cells cultured as in (D). 
(F) Relative abundance and proportion of the PEP pool labeled from U-[13C]-Q over 
time in A549 cells cultured as in (E). 
(G) Proportion of the m+6 mass isotopologue of citrate (top) and relative abundance 
of U-[13C]-Q incorporated into pyruvate (middle) and PEP (bottom) in H1299 cells 
cultured as in (B). 
(B-G) Data are represented as mean +/- SEM of three independent cultures. 
See also Figure S2. 
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Figure 3. PEP production from glutamine in glucose-starved cells is dependent 
on PCK2.  
(A) Immunoblot for PCK2 and actin on lysates from A549 and H1299 cells 
expressing control or PCK2 shRNA. PCK1(1) and PCK2(2) represent two different 
shRNAs targeting PCK2. 
(B) Schematic for proposed PCK2-mediated pyruvate cycling. Fully labeled OAA 
(m+4) is made from U-[13C]-Q. PCK2 activity produces fully labeled PEP (m+3) from 
OAA. Pyruvate can be made using PEP through the activity of pyruvate kinase and 
this can re-enter the TCA cycle as acetyl-CoA.  
(C) Relative abundance of U-[13C]-Q incorporation into PEP in A549 and H1299 cells 
expressing control or PCK2 shRNAs or upon treatment with the PEPCK inhibitor, 
MPA. Cells were cultured in the presence or absence of glucose for 12h, with U-[13C]-
Q added for the last 6h of incubation. Far right panel: A549 cells were treated with 
either DMSO (vehicle) or MPA throughout the 12h incubation.  
(D) Relative abundance of U-[13C]-Q incorporation into pyruvate in A549 and H1299 
cells expressing control or PCK2 shRNA or upon treatment with the PCK2 inhibitor, 
MPA. Cells were incubated as in (C). 
(C-D) Data are represented as mean +/- SEM of three independent cultures. 
See also Figure S3. 
 
Figure 4. Serine, glycine and ATP are made from glutamine upon glucose 
withdrawal in a PCK2-dependent manner. 
(A-D) U-[13C]-Q incorporation into serine and glycine in glucose starved cells. A549 
(A and B) or H1299 (C and D) cells were cultured for 12h in the presence or absence 
of glucose, followed by culture with U-[13C]-Q for the last 6h of the 12h incubation. 
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Shown is the proportion of the serine (A) or glycine (B) pools labeled by U-[13C]-Q in 
A549 cells over time. Levels of U-[13C]-Q-derived serine (C) and glycine (D) in 
glucose-starved H1299 cells is shown.  
(E-G) Relative abundance of U-[13C]-Q incorporation into serine (E and G) and 
glycine (F) in A549 cells expressing control and PCK2 shRNA (E and F) or upon 
treatment with MPA (G). Cells were cultured in the presence or absence of glucose 
for 12h, then cultured with U-[13C]-Q for the last 6h of the 12h incubation. (G) A549 
cells were treated with either DMSO (vehicle) or MPA throughout the 12h incubation.  
(H) Schematic of PCK2-mediated labeling of serine for OAA. Fully labeled OAA 
(m+4) is made from U-[13C]-Q. PCK2 activity produces fully labeled PEP (m+3) from 
OAA. Serine and glycine can be made using PEP through the activities of enolase and 
PHGDH. Abbreviations: 3-PG, 3-phosphoglycerate; Eno, enolase; PHGDH, 
phophoglycerate dehydrogenase. 
(I) Abundance of 13C-ATP in A549 cells cultured with U-[13C]-Q for 48h in the 
presence or absence of glucose. Cells were treated with either DMSO (vehicle) or 
MPA throughout the 48h incubation. 
(J) Mass isotopologues of the ATP pool in A549 cells cultured as in (I). 
(A-G and I-J) Data are represented as mean +/- SEM of three independent cultures. 
See also Figure S4. 
 
Figure 5. Cancer cells require PCK2 to maintain glucose-independent 
proliferation and tumor growth in vivo. 
(A) Proliferation of A549 and H1299 cells in glucose-free media over 96h following 
transfection with control or PCK2 siRNA.  
! 38!
(B) Proliferation of A549 cells in glucose free media over 96h following transfection 
with the indicated siRNAs.  
Each data point in A and B represents the average cell number of 5 wells in a 384 
well plate. 
(C-F) A549 and H1299 cells were injected into the flanks of nude mice. Growth of 
tumors derived from A549 cells expressing either control (n=6) or shRNA targeting 
PCK2 (n=7) (C) and from H1299 cells expressing either control (n=7) or shRNA 
targeting PCK2 (n=7) (D) is shown over 65 days. Tumor weights at the end of the 
experiment are also shown for A549 (D) and H1299 (F) cells. Data are represented as 
mean +/- SEM. 
See also Figure S5. 
 
Figure 6. PCK2 expression is regulated by glucose availability. 
(A) Relative expression of PCK2 mRNA as determined by qPCR. A549 cells were 
cultured in the presence or absence of glucose for up to 48h. Transcript levels were 
determined relative to ACTB mRNA levels, and normalized relative to expression at 
time 0. Data are represented as mean +/- SEM. 
(B) Immunoblot for PCK2 and actin on lysates from A549 and H1299 cells incubated 
in the presence or absence of glucose for 48h.  
(C) Relative expression of mRNA as measured by RNA-seq in A549 cells cultured in 
the presence or absence of glucose for 48h. Data were expressed relative to SUCLG2 
expression in cells grown under full glucose. Data are the mean +/- SEM of three 
independent cultures. 
! 39!
(D) Proliferation of A549 cells in glucose free media over 96h following transfection 
with indicated siRNAs. Each data point represents the average cell number of 5 wells 
in a 384 well plate (mean +/- SEM). 
 (E) Immunoblot for PCK2 and actin on lysates from A549 cells transfected with 
indicated siRNAs, then treated with or without glucose for 48h. 
(F) Growth of A549 cells in glucose-free medium over 96 hours. A549 cells were 
transfected with indicated siRNAs prior to seeding for growth assay. Each data point 
represents the average cell number of 5 wells in a 384 well plate (mean +/- SEM). 
See also Figure S6. 
 
Figure 7. PCK2 expression is increased in human cancer. 
(A) Boxplot of distribution of PCK2 mRNA expression levels relative to ACTB in 
TCGA cancer studies. Studies were selected to represent whole spectrum of 
expression levels. The boxplot was cropped at the relative expression value of 0.05. 
(B) Immunoblot for PCK2 on 3 individual samples of normal and tumor tissue 
samples from NSCLC patients. F1-ATPase was used as a control for protein loading. 
(C) Quantification of immunoblots for PCK2 expression from patient-matched normal 
and tumour tissues. Patients (n=29) are ranked based on percent change in PCK2 
expression in tumour samples relative to patient-matched normal tissue. Statistical 
significance was determined by a Kruskal-Wallis test, * p<0.05.  
See also Figure S7. 
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Inventory of Supplemental Information: 
 
Figure S1, related to Fig. 1. Metabolite analysis of A549 cells grown in the absence of 
glucose. 
 
Figure S2, related to Fig. 2. Glucose withdrawal redirects glutamine metabolism to 
maintain the TCA cycle and for the production of PEP. 
 
Figure S3, related to Fig. 3. TCA cycle metabolism in the absence of PCK2. 
 
Figure S4, related to Fig. 4. Serine, glycine and ATP are made from glutamine upon glucose 
withdrawal in a PCK2-dependent manner  
 
Figure S5, related to Fig. 5. Cancer cells require PCK2 to maintain glucose-independent 
proliferation and tumor growth in vivo.  
 
Figure S6, related to Fig. 6. PCK2 expression is regulated by glucose availability.  
 
Figure S7, related to Fig.7. PCK2 expression is elevated in NSCLC. 
 
Table S1, List of qPCR primers  
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!Figure S1, related to Fig. 1. Metabolite analysis of A549 cells grown in the absence of 
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!Figure S2, related to Fig. 2. Glucose withdrawal redirects glutamine metabolism to 
maintain the TCA cycle and for the production of PEP. 
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!Figure S3, related to Fig. 3. TCA cycle metabolism in the absence of PCK2. 
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!Figure S4, related to Fig. 4. Serine, glycine and ATP are made from glutamine upon glucose 
withdrawal in a PCK2-dependent manner.
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!Figure S5, related to Fig. 5. Cancer cells require PCK2 to maintain glucose-independent 
proliferation and tumor growth in vivo. 
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!Figure S6, related to Fig. 6. PCK2 expression is regulated by glucose availability. 
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!Figure S7, related to Fig.7. PCK2 expression is increased in NSCLC. 
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!Supplementary Figure Legends: 
 
Figure S1, related to Fig. 1. Metabolite analysis of A549 cells grown in the absence of 
glucose. 
A549 cells were cultured in the presence (+Glc) or absence of glucose (-Glc) for 48h and 
metabolite abundances determined using both LC- and GC-MS. The data are displayed as the 
log2 of the fold change in metabolite abundance between –Glc relative to +Glc conditions. Data 
are represented as mean +/- SEM of three independent cultures. 
 
Figure S2, related to Fig. 2. Glucose withdrawal redirects glutamine metabolism to 
maintain the TCA cycle and for the production of PEP. 
(A) Relative abundances of glutamate, α-KG, succinate, fumarate, malate, citrate and aspartate 
after culture of A549 cells for 12h in the presence or absence of unlabeled glucose (Glc). Cells 
were cultured with U-[13C]-Q for the last 6h of the 12h incubation. Data are presented relative to 
metabolite abundance in glucose-replete conditions (+Glc).   
(B) Model for U-[13C]-Q flux in the TCA cycle under glucose withdrawal. In the absence of 
glucose fully labeled TCA cycle intermediates made from U-[13C]-Q can be used to make fully 
labeled pyruvate and PEP (m+3). Pyruvate m+3 can re-enter the TCA cycle, as acetyl-CoA 
(m+2), which condenses with fully labeled OAA (m+4) to give citrate m+6. Abbreviation: PEP, 
phosphoenolpyruvate. 
(C) Relative abundance of lactate in A549 cells cultured with U-[13C]-Q as in (A). 
(D) The contribution of mass isotopologues (unlabeled m+0 or fully-labeled m+3) to the total 
pyruvate, PEP and lactate pools in A549 cells cultured with U-[13C]-Q as in (A).  
!Data are represented as mean +/- SEM of three independent cultures. 
 
Figure S3, related to Fig. 3. TCA cycle metabolism in the absence of PCK2. 
(A) Immunoblot for total PEPCK and actin on lysates from A549 cells transfected with either 
control siRNA or siRNA targeting either PCK1 or PCK2. Cells were incubated in the presence or 
absence of glucose for 48h. 
(B) Contribution of U-[13C]-Q to PEP in A549 cells expressing either control shRNA or shRNA 
targeting PCK2 in glucose free conditions. Cells were pre-incubated in the absence of glucose for 
6h before incubation with U-[13C]-Q (time 0). Cells extracts were harvested at the time points 
shown.  
(C) Relative abundances of glutamate, α-KG, succinate, fumarate, malate, citrate and aspartate in 
A549 cells expressing control or PCK2 shRNA. Cells were cultured in the presence or absence of 
unlabeled glucose for 12h, and cultured with U-[13C]-Q for the last 6h of the 12h incubation. Data 
are made relative to metabolite abundance in glucose-replete conditions (+Glc).  
(D) Proportion of mass isotopologue citrate m+6 in A549 and H1299 cells expressing control or 
PCK2 shRNA. Cells were cultured in the presence or absence of glucose as in (C).  
(B-D) Data are represented as mean +/- SEM of three independent cultures. 
 
Figure S4, related to Fig. 4. Serine, glycine and ATP are made from glutamine upon glucose 
withdrawal in a PCK2-dependent manner. 
(A-B) Relative abundances of serine and glycine and the contribution of U-[13C]-Q to these 
metabolites in A549 cells (A) or H1299 cells (B).  Cells were cultured in the absence or presence 
of unlabeled glucose for 12h, with U-[13C]-Q being present for the last 6h of the 12h incubation. 
!(C-D) Contribution of the mass isotopologues of serine (C) and glycine (D) to the total 
metabolite pool in A549 cells. Cells were incubated with U-[13C]-Q in the presence or absence of 
glucose for 48h before cells extracts were harvested.  
(E-F) Contribution of U-[13C]-Q to serine (E) and glycine (F) in A549 cells expressing either 
control shRNA or shRNA targeting PCK2 in glucose free conditions. Cells were pre-incubated in 
the absence of glucose for 6h before incubation with U-[13C]-Q (time 0). Cells extracts were 
harvested at the time points shown.  
(G) Immunoblot for enolase, PHGDH and actin on lysates from A549 cells 3 days post 
transfection with either control siRNA or siRNA targeting either ENO1 or PHGDH.  
(H) Relative abundance of 13C-serine in A549 cells transfected with either control siRNA or 
siRNA targeting either ENO1 or PHGDH. Cells were cultured as in (A). 
(A-F and H) Data are represented as mean +/- SEM of three independent cultures 
 
Figure S5, related to Fig. 5. Cancer cells require PCK2 to maintain glucose-independent 
proliferation and tumor growth in vivo. 
(A) Immunoblot for PCK2 and actin on lysates from A549 and H1299 cells 3 days post 
transfection with either control siRNA or siRNA targeting PCK2. 
 (B) Proliferation of A549 cells expressing either control shRNA or shRNA targeting PCK2 in 
glucose-free media over 96 hours. Data are represented as mean +/- SEM for biological replicates 
(n=5). 
(C) A549 cells transfected with siRNA targeting PCK2, ENO1 or PHGDH were cultured for 48h 
in the presence or absence of glucose before staining with propidium iodide to measure the 
percentage of viable cells. Data are represented as mean +/- SEM of three independent cultures. 
!(D-G) Immunoblot for PCK2 and actin on lysates from A549 (D) and H1299 (F) cells, expressing 
either control or shRNA targeting PCK2, injected into the flanks of nude mice. Immunoblot for 
PCK2 and actin on lysates from the resulting tumors (where enough tissue was available) formed 
from the A549 (E) and H1299 (G) cells injected.  
 
Figure S6, related to Fig. 6. PCK2 expression is regulated by glucose availability. 
(A) Immunoblot for SUCLG2, SUCLA2 and actin on lysates from A549 cells 3 days post 
transfection with either control siRNA or siRNA targeting either SUCLG2 or SUCLA2. 
 (B) Expression of HIF1A and EPAS1 mRNA in A549 cells. A549 cells transfected with control 
siRNA or siRNA targeting HIF1A, EPAS1 or a combination of both were incubated in the 
presence or absence of glucose for 48h. Transcript levels for HIF1A or EPAS1 mRNA were 
determined relative to OGDH mRNA levels, and normalized relative to control cells (transfected 
with control siRNA). ***, p<0.001. 
(C) Relative expression of PCK2 mRNA as determined by qPCR. A549 cells transfected with 
siRNA against HIF1A, EPAS1 or a combination of both were cultured in the presence or absence 
of glucose for 48h. PCK2 mRNA transcript levels were determined relative to OGDH mRNA 
levels, and normalized relative to expression in cells transfected with control siRNA. **, p<0.01. 
(B-C) Data are represented as mean +/- SEM of three independent cultures.  
 
Figure S7, related to Fig.7. PCK2 expression is increased in NSCLC. 
Quantified proteomic data from 29 NSCLC patients. Each bar represents the average expression 
of PCK2 in 3 pieces of normal tissue (black bars) or 3 pieces of tumour tissue (white bars) for 
!each patient (mean +/- SEM). The strength of evidence for a difference in expression between the 
normal and tumour samples was determined by a Kruskal-Wallis test, *, p<0.05.  
  
!Table S1: List of qPCR primers  
Gene Forward Primer Reverse Primer 
PCK2 TGCCAGGCTGGAAAGTGGAGTGT GCAACCCCAAAGAAGCCGTTCTCA 
HIF1A TGCTCATCAGTTGCCACTTCC CGCTGTGTGTTTTGTTCTTTACCC 
EPAS1 GCCTCCATCATGCGACTGGCA CCATCTTGGGTCACCACGGCA 
OGDH AGACCCCTGGGATCATGCAGTTCA CCTCGCAGCCTTCTAGACCAAAGC 
PCK1 CTGTGACGGCTCTGAGGAGGAGA
A 
CCACATCCCTGGGGTCAGTGAGAG 
  
  
!Supplementary Experimental Procedures: 
Materials 
The PEPCK inhibitor 3-mercaptopicolinic acid (MPA) was obtained from Santa Cruz 
Biotechnology (Dallas, TX, USA). Primary antibodies to PCK2 and actin, as well as HRP-
conjugated anti-rabbit and anti-mouse secondary antibodies were obtained from Cell Signaling 
Technology (Danvers, MA, USA). Primary antibody to α-enolase was obtained from Santa Cruz 
Biotechnology (Dallas, TX, USA). PHGDH antibodies were obtained from Thermo Fisher 
(Waltham, MA, USA). Primary antibodies to SUCLG2 and SUCLA2 were obtained from Novus 
Biologicals (Littleton, CO, USA). 
 
Cell culture 
A549 and H1299 cell lines were obtained from ATCC (Manassas, VA, USA). Cells were 
cultured in ‘growth medium’ (DMEM (A549 cells) or RPMI (H1299 cells)) supplemented with 
10% fetal bovine serum (FBS), 20000U/ml penicillin, 7mM streptomycin and 2mM glutamine 
and non-essential amino acids (for H1299 cells). Cells were grown at 37°C in a humidified 
atmosphere supplemented with 5% (v/v) CO2. For experiments cells were cultured in DMEM 
with 20000U/ml penicillin, 7mM streptomycin and 10% dialysed FBS (Wisent, Saint-John-
Baptiste, QC, Canada), 2mM glutamine and 25mM glucose were then added as required.  
 
shRNA and siRNA knockdown 
PCK2 knockdown was achieved using lentiviral shRNA vectors (ID numbers: TRCN0000052664 
and TRCN0000052666) from the TRC shRNA collection (Sigma-Aldrich, St. Louis, MO). 
Lentiviral supernatants were generated as described (Huang et al., 2012). All transient 
!knockdowns in this manuscript were achieved using the SMARTpool ON-TARGETplus siRNA 
reagent (composed of 4 individual siRNAs for each target) from GE Dharmacon (Layette, CO, 
USA). 50nM siRNA was incubated for 20min with RNAimax in OptiMEM medium (Life 
Technologies) in a 12 well plate, followed by seeding of cells (60,000 cells/well). Cells were 
transfected a second time 48 hours later, and cells plated for assays the following day. 
 
RNA-Seq analysis 
A549 cells were cultured in the presence (25 mM) or absence of glucose for 48 hours prior to 
RNA extraction. For cDNA synthesis, custom oligo-dT primers were used with a barcode and 
adapter-linker sequence (CCTACACGACGCTCTTCCGATCT—XXXXXXXX-T15). After first 
strand synthesis, samples were pooled together based on ACTB qPCR values, and RNA-DNA 
hybrids degraded using consecutive acid-alkali treatment. A second sequencing linker 
(AGATCGGAAGAGCACACGTCTG) was ligated using T4 ligase (NEB) followed by SPRI 
clean-up. The mixture was then PCR enriched for 12 cycles and SPRI purified to yield final 
strand specific RNA-seq libraries as previously described (Jha et al., 2015). Libraries were 
sequenced using a HiSeq 2500 (Illumina) using 50bpX25bp pair-end sequencing. Second mate 
was used for sample demultiplexing, at which point individual single-end fastqs were aligned to 
mm9 genome using TopHat. and gene expression was obtained using ht-seq and DESeq2 for 
differential expression. Raw and processed sequencing data are deposited at Pubmed GEO under 
GSE66556. 
 
Metabolite profiling by LC-MS  
!Liquid chromatography was performed using a 1290 Infinity ultra-performance LC system 
(Agilent Technologies, Santa Clara, CA, USA) equipped with a Scherzo 3 μm, 3.0×150mm SM-
C18 column (Imtakt Corp, Japan). The column temperature was maintained at 10°C and the 
mobile phases A and B consisted of water containing 5 and 200mM ammonium acetate, 
respectively. The chromatographic gradient started at 100% mobile phase (A) with a 5 min 
gradient to 100% (B). This was followed by a 5min hold time at 100% mobile phase B at a flow 
rate of 0.4ml/min. A subsequent re-equilibration time (6min) was performed before the next 
injection. Sample volumes of 5μl were injected for LC-MS analysis. LC-MS analysis was 
performed on an Agilent 6540 UHD Accurate-Mass Q-TOF mass spectrometer (Agilent 
Technologies, Santa Clara, CA, USA). Analyte ionization was accomplished using an 
electrospray ionization source (ESI) in both positive and negative polarities. The source operating 
conditions were set at 325°C and 9l/min for gas temperature and flow respectively, nebulizer 
pressure was set at 40psi and capillary voltage was set a 4.0kV. Reference masses 121.0509, 
922.0099, 1033.9881 were introduced into the source through a secondary spray nozzle to ensure 
accurate mass. MS data were acquired in full scan mode mass range: m/z 100-1000; scan time: 
1.4s; data collection: centroid and profile. Retention times, and accurate mass for each compound 
were confirmed against authentic standards as well as matched unlabeled cell extracts grown 
under the same conditions when cells were undergoing stable isotope tracer analysis (SITA). 
Data were quantified by integrating the area underneath the curve of each compound using 
MassHunter Qual (Agilent Technologies, Santa Clara, CA, USA). Each metabolite’s accurate 
mass ion and subsequent isotopic ions were extracted (EIC) using a 10 ppm window. 
 
Network-based data integration 
!Network-based integration of metabolite and gene expression datasets was conducted as 
previously described (Jha et al., 2015). A chemical mapping table between carbon atoms in 
substrates and products for all annotated reactions in the KEGG database using RPAIRs entries 
was made (Kanehisa et al., 2012). Only those atoms that could be uniquely identified by the 
chemical structure (i.e. constant between different stereoisomers) were used. Using such a 
chemical mapping table we built a network of individual carbon atoms connected by a substrate-
product relationship via biochemical reactions. Each metabolite is present in the network through 
a number of disconnected nodes representing individual carbon atoms within the metabolite, with 
common metabolites (i.e. water, ATP, NAD) removed from the network to avoid redundancy. At 
the final filtering stage only reactions catalyzed by enzymes with significant expression levels 
were kept. The top 12000 expressed genes were used as a cutoff, to generate a network 
containing approximately 6000 nodes and 6000 edges. 
To search for sub-networks upregulated by glucose deprivation, network nodes and edges 
were assigned a score by differential expression analysis using DESeq2 (Love et al., 2014). The 
actual score was a sum of log2 mean gene expression and value of DE test statistic minus a 
threshold value that was a parameter to reflect importance of both basal expression level and 
differential regulation of the enzyme. To assign a score to the nodes, we performed a t-test on 
metabolite levels in two conditions, and used the logarithm of the p-value as the node score. 
Metabolites that were not measured had a score of zero. In the scored network we used a heuristic 
algorithm to find the most connected sub-network with maximal total node and edge scores. 
Threshold values were selected to create a sub-network with 100-150 metabolites. This sub-
network was then enriched in reaction edges, connecting the metabolites provided the 
corresponding enzymes were highly expressed (top 6000 by expression, irrespective of their 
!differential expression). Finally multiple atoms of the same compound were collapsed to yield a 
network containing a single node for each compound to ease visualization and interpretation.  
 
NSCLC patients and tissue samples 
The study was approved by the local research ethics committee: UK National South West 4 
Research Ethics Committee (REC) Southmead Hospital, Bristol BS10 5NB. REC no: 
07/Q2002/6, South West 4 REC.  
Three distinct samples of the tumour and adjacent normal tissue from the resection 
margin were taken, flash frozen in liquid nitrogen, and stored at −80°C until further analysis. 
Only those NSCLC tumour samples comprising at least 90% tumour tissue were analyzed. 
Frozen tissue samples were homogenized and extracted as previously described. Briefly, a 
Polytron homogenizer was used to generate tissue lysates in 1% NP40 lysis buffer. Protein 
concentration was determined by BCA assay (Thermo Scientific, IL, USA) and tissue lysates 
were stored at −80°C. 
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